Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1768380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia.
J Med Cases
October 2024
Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Article Synopsis
- * A case study details a 75-year-old Hispanic male with relapsed/refractory Philadelphia-positive B-cell ALL, who was treated with multiple TKIs and chemotherapy, culminating in a novel combination of ponatinib and asciminib before and after brexu-cel therapy.
- * This combination of ponatinib and asciminib proved to be effective, controlling the disease for 2 months before brexu
[Sustaining molecular response with very low dose ponatinib and further response after hemodialysis initiation in a patient with chronic myeloid leukemia].
Rinsho Ketsueki
November 2023
Department of Hematology, Nagano Red Cross Hospital.
Article Synopsis
- A 46-year-old man diagnosed with chronic myeloid leukemia (CML) failed initial treatments with multiple tyrosine kinase inhibitors due to a specific mutation.
- After starting ponatinib (PON) at age 66, he achieved a complete cytogenetic response (CCyR) within three months but faced complications leading to dosage adjustments.
- Eventually, after experiencing a deep molecular response for three years, his treatment was restarted after losing response, and he has been maintaining his response at age 77, with improvements possibly linked to hemodialysis.
Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation.
Eur J Haematol
January 2024
Stem Cell Transplantation and Cellular Therapies Unit, Grande Ospedale Metropolitano, "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Relapsed or refractory (r/r) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) still represent an unmet clinical need despite the new immune therapies available for these patients. We report the case of a Ph + ALL relapsed one year after allogeneic stem cell transplant. After one DLI was started CAR-T program with brexucabtageneautoleucel, using as bridging treatment ponatinib, vincristine and prednisone.
View Article and Find Full Text PDFThe evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
J Hematol Oncol
March 2023
Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX, 77030, USA.
Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 2022 across ALL subtypes. In Philadelphia chromosome-positive ALL, the addition of BCR::ABL1 tyrosine kinase inhibitors (TKIs) to intensive chemotherapy since 2000, improved outcomes.
View Article and Find Full Text PDFCase report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia.
Front Oncol
January 2023
Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) constitutes a heterogeneous subset of ALL with a uniformly unfavorable prognosis. The identification of mutations amenable to treatment with tyrosine kinase-inhibitors (TKIs) represents a promising field of investigation. We report the case of a young patient affected by relapsed/refractory Ph-like ALL treated with chimeric antigen receptor T (CAR-T) cells after successful bridging with compassionate-use ponatinib and low-dose prednisone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!